Thanks Rajenp5, was this in the melanoma trial? This is obviously starting to stretch my understanding of cancers but why would they be targeting proximal tumours in a melanoma trial?
Was this adverse reaction published anywhere? Surely they would not pursue further trials if there was a drug fail issue...
